Reference:	FOI.10877.23
Subject:	Biologic medicines in gastroenterology
Date of Request:	6 February 2023

Requested:

1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
   Adalimumab - Humira
   Adalimumab Biosimilar
   Filgotinib
   Golimumab
   Infliximab - Remicade
   Infliximab Biosimilar
   Ozanimod
   Tofacitinib
   Upadacitinib
   Ustekinumab
   Vedolizumab

2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs:
   Adalimumab - Humira
   Adalimumab Biosimilar
   Golimumab
   Infliximab - Remicade
   Infliximab Biosimilar
   Upadacitinib
   Ustekinumab
   Vedolizumab

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for question 2, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the data requested, the UHB would need to undertake a manual trawl of all of the patients identified as being diagnosed with Crohn's Disease and cross-reference with the Pharmacy systems, to identify the information, as it is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, we are required as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under the FoIA. Therefore, the UHB provides the information it holds and is accessible for question 1 below.

1. The UHB provides, within the table below, the number of UHB patients treated by the Gastroenterology Department, with the listed biologic medicines, during the period 1 November 22 to 31January 2023.

Medicine	Number
Adalimumab – Humira	14
Adalimumab Biosimilar	98
Filgotinib	*
Golimumab	0
Infliximab – Remicade	0
Infliximab Biosimilar	65
Ozanimod	0
Tofacitinib	8
Upadacitinib	14
Ustekinumab	110
Vedolizumab	81

Where the figure in the table has been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act (DPA) 2018/General Data Protection Regulations (GDPR) 2016, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 define personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.